# CMB International Securities | Equity Research | Company Update

# Yili (600887 CH)

# Four measures to offset raw milk pressure

3Q20 NP +24% YoY to RMB2,289mn, 9% above consensus due to RMB94mn/82mn YoY increase of fair value gain/other income. The 10% share price drop last Friday was partly because share price already ran ahead of 3Q20 results release. Share price jumped 9% from 23 to 29 Oct (vs MN's 1% drop). We think Yili will implement four measures to offset raw milk pressure, and therefore we kept FY21/22E NP estimates unchanged. We expect Yili would continue to benefit from industry consolidation. Maintain Buy.

- 3Q20 NP beat but GPM missed. Revenue rose 11% YoY in 3Q20, which is in line with consensus and our expectation, led by 19%/10%/1% growth of milk powder/liquid milk/ice-cream segments. GPM fell 1.3ppt to 34.7% because of 6-7% raw milk price growth (RMB4.5kg in 3Q20 vs China Modern Dairy's ASP ~RMB4.2/kg) and dilution by Westland. That said, selling expenses ratio fell 1.4ppt to 20.5%, offsetting the impact of GPM decline.
- Four measures to offset raw milk pressure. Management expects raw milk price to grow by high single-digit in 2H20E and increase further in FY21E. (1) Reduce discount promotion: Our sources of channel check found retail prices of Satine rose to RMB65 in second half of Oct (highest level since Feb) and so did MN's Milk Deluxe (Figure 4 & 5). Management expects the sector would be more disciplined in promotions. (2) Control raw milk source: Yili became the largest shareholder of Zhongdi (1492 HK) in Sep and its associate company, Youran, bought two farms from Fonterra China in Oct. (3) Product innovation: For example, Ambrosial launched a high-end 5G protein in Aug and Satine will launch a high-end 4.0g UHT milk in 1Q21. The retail price/gram of 5G protein is more than double of Ambrosial original favour (Figure 6 & 7). (4) Improve efficiency of selling expenses: Selling expenses ratio fell 0.9ppt to 22.7% in 9M20 through more precise marketing such as online advertising. It's 12.3% A&P exp. ratio in FY19 was higher than many major consumer names (Figure 9). As dairy sector leader, we think Yili has room to improve efficiency. Management expects slight drop of selling expenses ratio in FY21E.
- To become global top three dairy company in 2025. The Company targets to become global top 3 dairy players in 2025 and the largest player in 2030. In the 14th five year period, Yili will strengthen its leadership and growth in dairy sector, while sales contribution by non-dairy products and overseas market will not be significant. At a 10% sales CAGR in 2019-25, we believe Yili could reach top 3 in 2025 (Figure 8).
- Maintain Buy. We lifted FY20E NP by 4% to reflect strong 3Q20 results and maintain our NP estimates in FY21/22E. Our TP is kept at RMB45.90, still based on 32x FY21E P/E. Catalysts: better-than-expected revenue and margins. Risks: Raw milk cost pressure, food safety issues.

## **Earnings Summary**

(YE 31 Dec)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue (RMB mn)	78,976	90,009	96,852	108,639	119,549
YoY growth (%)	17	14	8	12	10
Net profit (RMB mn)	6,440	6,934	7,414	8,763	10,105
EPS (RMB)	1.060	1.150	1.216	1.437	1.658
YoY growth (%)	7	8	6	18	15
Consensus EPS (RMB)	na	na	1.174	1.391	1.608
P/E (x)	37.5	34.5	32.7	27.6	24.0
P/B (x)	8.7	9.3	8.5	7.5	6.7
Yield (%)	1.8	2.0	2.1	2.5	2.9

Source: Company data, Bloomberg, CMBIS estimates



# **BUY (Maintain)**

Target Price	RMB45.90
(Previous TP	RMB45.90)
Up/Downside	+16%
Current Price	RMB39.73

#### China F&B Sector

Albert Yip (852) 3900 0838 albertyip@cmbi.com.hk

#### Stock Data

Mkt Cap (HK\$ mn)	241,686
Avg 3 mths t/o (HK\$ mn)	2,211.39
52w High/Low (HK\$)	44.54/ 26.89
Total Issued Shares (mn)	5,907.5
Source: Bloomberg	

#### **Shareholding Structure**

Huhhot Investment 8.85% Source: HKEx

#### Share Performance

	Absolute	Relative
1-mth	15.3%	13.6%
3-mth	23.1%	23.9%
6-mth	50.7%	30.0%
Source: Bloomberg	1	

#### 12-mth Price Performance



Source: Bloomberg

#### Auditor: Da Hua

#### **Related reports**

- 1. "Yili 2Q20 strongly beat; TP lifted to RMB45.90" – 31 Aug 2020
- "Yili Expect full recovery of sales by Jun" – 4 May 2020
- "China Dairy Sector Multiple growth drivers ahead; sector consolidation to continue" – 19 Nov 2019



# Figure 1: 3Q20 results review

Y/E Dec (RMB mn)	3Q20	3Q19	change (%)	Remarks
Revenue	26,162	23,552	(70)	Satine growth improved from 10% in 1H to 15% in
Revenue	20,102	23,332	1170	9M. Ambrosial returned to growth in 3Q
Cost of sales	(17,077)	(15,075)	13%	
Gross profit	9,084	8,477	7%	
Other income and gains/(losses)	422	198	113%	RMB94mn/82mn increase of FV gain/other income
Selling and distribution expenses	(5,363)	(5,149)	4%	
Administrative expenses	(1,242)	(1,060)	17%	
R&D expenses	(124)	(132)	-6%	
Tax & surcharges	(135)	(118)	15%	
Other expenses	(33)	4	-841%	
Operating profit	2,610	2,221	17%	
Finance income, net	(17)	(101)	-83%	
Other gains/(losses)	7	(12)	-156%	
Share of profit from JV/associate	111	56	100%	
Profit before tax	2,710	2,164	25%	
Tax expense	(423)	(314)	35%	
Profit after tax	2,287	1,850	24%	
Non-controlling interests	2	0	2184%	
Net profit	2,289	1,850	24%	
Margin & Ratio (%)				
Gross margin	34.7	36.0	(1.3)	Raw milk+6-7% and dilution by Westland
Operating margin	10.0	9.4	0.5	
Selling expenses ratio	20.5	21.9	(1.4)	
Administrateive expenses ratio	4.7	4.5	0.1	
R&D expenses ratio	0.5	0.6	(0.1)	
Net margin	8.7	7.9	0.9	
Effective tax rate	15.6	14.5	1.1	

Source: Company, CMBIS

# Figure 2: Earnings revision

	New				Old		Diff (%)			
US\$ mn	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	
Revenue	96,852	108,639	119,549	97,286	108,915	119,932	0%	0%	0%	
Gross Profit	35,494	40,349	44,875	36,235	41,195	45,721	-2%	-2%	-2%	
Operating Profit	8,915	10,061	11,474	8,585	10,126	11,560	4%	-1%	-1%	
Net Profit	7,415	8,763	10,105	7,107	8,745	10,124	4%	0%	0%	
Gross Margin	36.6%	37.1%	37.5%	37.2%	37.8%	38.1%	-0.6ppt	-0.7ppt	-0.6ppt	
Operating Margin	9.2%	9.3%	9.6%	8.8%	9.3%	9.6%	+0.4ppt	flat	flat	
Net Margin	7.6%	7.9%	8.2%	7.4%	7.9%	8.2%	+0.2ppt	flat	flat	

Source: Company data, CMBIS estimates

# Figure 3: CMBIS estimates vs consensus

		CMBIS			Consensus			Diff (%)	
US\$ mn	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Revenue	96,852	108,639	119,549	98,709	110,995	123,418	-2%	-2%	-3%
Gross Profit	35,494	40,349	44,875	36,730	41,659	46,571	-3%	-3%	-4%
Operating Profit	8,915	10,061	11,474	8,554	9,898	11,338	4%	2%	1%
Net profit	7,415	8,763	10,105	7,128	8,556	9,814	4%	2%	3%
Gross Margin	36.6%	37.1%	37.5%	37.2%	37.5%	37.7%	-0.6ppt	-0.4ppt	-0.2ppt
Operating Margin	9.2%	9.3%	9.6%	8.7%	8.9%	9.2%	+0.5ppt	+0.4ppt	+0.4ppt
Net Margin	7.6%	7.9%	8.2%	6.6%	7.6%	7.6%	+1.0ppt	+0.3ppt	+0.6ppt

Source: Bloomberg, CMBIS estimates

Figure 4: Retail price of Satine (250mL\*12) was lifted to RMB65.0 in a supermarket in Hunan in late Oct

Source: CMBIS

Source: CMBIS

Figure 6: Retail price of 5G yogurt (125g\*8) was set at RMB79.20, representing RMB0.08/g which is more high-end than Ambrosial original favour

Henr 512 50 882

883

58

58

also lifted to RMB58.0 in Hunan in late Oct

1125

59-

58

58

-

10

1126

58

58

Source: CMBIS

Figure 5: Retail price of Mlik Deluxe (250mL\*12) was

Figure 7: Retail price of Ambrosial original favour

Source: CMBIS

(205g\*12) was lifted to RMB66.0 in a supermarket in Hunan in late Oct, representing RMB0.03/g









HER

88

58

58

HEAT

3



# Figure 8: Global top 10 companies in terms of dairy turnover

	2019	2019-25	2025E
	US\$bn	CAGR	US\$bn
Nestle	22.1	4.0%	28.0
Lactalis	21.0	2.5%	24.4
Dairy Farmers of America	20.1	2.5%	23.3
Danone	18.2	4.0%	23.0
Yili	13.4	10.0%	23.7
Fonterra	13.2		
FrieslandCampina	12.6		
Mengniu	11.9		
Arla Foods	11.8		
Saputo	11.3		

Source: Rabobank, CMBIS estimates

# Figure 9: A&P expenses and exp ratio of major consumer companies

	A&P exp ratio	RMB mn
Yili	12.3%	11,041
Feihe *	17.1%	1,775
Mengniu	10.8%	8,500
Anta	10.6%	3,596
Li Ning	9.6%	1,327
Nongfu Spring	5.1%	1,219
Hengan	5.1%	1,137
Haitian Flavour	4.3%	860
Tsingtao Brewery	3.4%	864
Moutai	3.1%	2,975
Want Want	2.9%	583

Source: CMBIS estimates \*FY18 figure


## Figure 10: Market shares of ambient and chilled products are increasing



Source: Company data, Nielsen



# Figure 11: P/E band chart



Source: CMBIS estimates, Bloomberg, Company data



# **Financial Summary**

Income statement						Cash flow summary					
YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E	YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue	78,976	90,009	96,852	108,639	119,549	Profit before tax	7,578	8,194	8,696	10,318	11,895
Liquid milk	65,679	73,761	77,043	86,807	95,799	JV & associates	(144)	(214)	(332)	(472)	(552)
Milk powder	8,045	10,055	12,860	14,243	15,591	D&A	1,598	1,891	2,373	2,812	3,142
Ice-cream	4,997	5,631	6,214	6,782	7,261	Net finance income	(60)	8	131	129	44
Others	833	776	1,036	1,107	1,198	Change in working capital	313	3,312	744	1,042	1,009
Cost of sales	(49,106)	(56,392)	(61,358)	(68,290)	(74,674)	Others	(660)	(4,736)	(763)	(1,336)	(1,570)
Gross profit	29,870	33,617	35,494	40,349	44,875	Operating cash flow	8,625	8,455	10,849	12,494	13,969
Other income	1,402	1,125	1,278	1,113	1,142	Capex	(5,091)	(9,243)	(8,000)	(6,000)	(3,000)
Selling expenses	(19,773)	(21,070)	(21,792)	(24,770)	(27,377)	Acquisitions	0	(1,617)	(1,467)	0	0
Admin expenses	(2,980)	(4,285)	(4,843)	(5,215)	(5,619)	Others	(284)	861	(828)	138	138
Other op expenses	(1,033)	(1,314)	(1,223)	(1,415)	(1,549)	Investing cash flow	(5,375)	(9,999)	(10,295)	(5,862)	(2,862)
EBIT	7,486	8,075	8,915	10,061	11,474	-					
						Change of debt	(6,337)	6,633	8,431	(3,000)	(2,500)
Finance income, net	60	(8)	(131)	(129)	(44)	Dividend and interest paid	(4,393)	(4,406)	(5,507)	(5,706)	(6,565)
Other gains/(losses)	(113)	(86)	(420)	(86)	(86)	Others	(19)	(3,244)	0	0	0
JV & associates	144	214	332	472	552	Financing cash flow	(10,749)	(1,016)	2,924	(8,706)	(9,065)
Pre-tax profit	7,578	8,194	8,696	10,318	11,895	-					
Income tax	(1,126)	(1,243)	(1,263)	(1,536)	(1,770)	Net change in cash	(7,499)	(2,560)	3,478	(2,075)	2,042
Less: Minority interests	(12)	(17)	(19)	(19)	(20)	Cash at the beginning	20,756	13,564	11,066	14,544	12,469
Net profit	6,440	6,934	7,414	8,763	10,105	Exchange difference	307	62	0	0	0
						Cash at the end	13,564	11,066	14,544	12,469	14,511

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E	YE 31 Dec	FY18A	FY19A	FY20E	FY21E	FY22E
Non-current assets	23,151	34,755	42,231	45,940	46,399	Sales mix (%)					
Fixed asset	17,374	24,461	30,138	33,374	33,281	Liquid milk	83.2	81.9	79.5	79.9	80.1
Prepaid lease payments	650	1,936	1,936	1,936	1,936	Milk powder	10.2	11.2	13.3	13.1	13.0
Interest in JV	1,909	1,961	3,760	4,232	4,784	Ice-cream	6.3	6.3	6.4	6.2	6.1
Other non-current assets	3,217	6,397	6,397	6,397	6,397	Others	1.1	0.8	0.8	0.7	0.7
Current assets	24,455	25,706	30,832	30,097	33,375	P&L ratios (%)					
Inventories	5,507	7,715	8,395	9,343	10,216	Gross margin	37.8	37.3	36.6	37.1	37.5
Account receivables	1,282	1,837	1,977	2,217	2,440	EBIT margin	9.5	9.0	9.2	9.3	9.6
Prepayments	1,614	1,352	1,440	1,591	1,732	Net margin	8.2	7.7	7.7	8.1	8.5
Others	5,001	3,476	4,476	4,476	4,476	Payout ratio	66.1	70.9	70.0	70.0	70.0
Cash	11,051	11,325	14,544	12,469	14,511						
						Balance sheet ratios					
Current liabilities	19,171	31,432	37,514	38,396	38,142	Current ratio (x)	1.3	0.8	0.8	0.8	0.9
Account payables	9,116	10,801	11,753	13,080	14,303	Quick ratio (x)	1.0	0.6	0.6	0.5	0.6
Other payables	8,135	12,262	12,962	14,016	15,039	A/C receivables days	5	6	7	7	7
Borrowings	1,556	4,866	9,366	9,866	8,366	A/C payables days	62	64	67	66	67
Tax payables	353	397	397	397	397	Inventory days	38	43	48	47	48
Others	10	3,106	3,037	1,037	37	Net cash (RMB mn)	9,495	4,488	(3,793)	(2,868)	1,674
Non-current liabilities	398	2,755	6,755	5,255	5,255	Returns (%)					
Borrowings	0	1,971	5,971	4,471	4,471	ROAE	24.3	25.7	27.1	28.8	29.6
Others	398	784	784	784	784	ROAA	13.3	12.8	11.1	11.8	13.0
Total net assets	28,037	26,274	28,794	32,386	36,378	Per share					
Shareholders' equity	27,916	26,131	28,632	32,205	36,176	EPS (RMB)	1.06	1.15	1.22	1.44	1.66
Non-controlling interests	122	143	162	181	202	DPS (RMB)	0.70	0.81	0.85	1.01	1.16
· · · · · · · · · · · · · · · · · · ·						BVPS (RMB)	4.59	4.29	4.70	5.28	5.93
Source: Company data CM		otoo				- ( /					

Source: Company data, CMBIS estimates



# **Disclosures & Disclaimers**

## **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIS
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

#### CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

#### Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

#### For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

#### For recipients of this document in the United States

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investors a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.